Steve Doberstein

Steve Doberstein is an experienced and innovative leader of pharmaceutical Research and Development organizations. For the last decade, Steve was Chief Scientific Fellow and Chief Research and Development Officer at Nektar Therapeutics. He was previously Vice President of Research at Xoma, FivePrime, and Xencor, having started his career at Exelixis.

Steve studied Chemical Engineering at the University of Delaware, receiving a B.S.Ch.E., and studied molecular and cell biology at the Johns Hopkins University School of Medicine, where he was awarded a Ph.D. from the laboratory of Dr. Thomas Pollard. He studied genetics as a postdoctoral fellow in the laboratory of Dr. Corey Goodman at UC Berkeley.

Steve currently serves on the Board of Directors of Dicerna Pharmaceuticals (DRNA).